Oral administration of PF-01247324, a subtype-selective Nav1.8 blocker, reverses cerebellar deficits in a mouse model of multiple sclerosis.
Cerebellar symptoms significantly diminish quality of life in patients with multiple sclerosis (MS). We previously showed that sodium channel Nav1.8, although normally restricted to peripheral somatosensory neurons, is upregulated in the cerebellum in MS, and that Nav1.8 expression is linked to atax...
Main Authors: | Shannon D Shields, Richard P Butt, Sulayman D Dib-Hajj, Stephen G Waxman |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | https://doi.org/10.1371/journal.pone.0119067 |
Similar Items
-
A Gain-of-Function Mutation in Nav1.6 in a Case of Trigeminal Neuralgia
by: Brian S Tanaka, et al.
Published: (2016-08-01) -
Paclitaxel effects on axonal localization and vesicular trafficking of NaV1.8
by: Christopher A. Baker, et al.
Published: (2023-02-01) -
Conserved but not critical: Trafficking and function of NaV1.7 are independent of highly conserved polybasic motifs
by: Sidharth Tyagi, et al.
Published: (2023-03-01) -
Expression of Nav1.7 in DRG neurons extends from peripheral terminals in the skin to central preterminal branches and terminals in the dorsal horn
by: Black Joel A, et al.
Published: (2012-11-01) -
A Novel Gain-of-Function Nav1.9 Mutation in a Child With Episodic Pain
by: Jianying Huang, et al.
Published: (2019-09-01)